Kisqali

Active Ingredient(s): Ribociclib
FDA Approved: * March 13, 2017
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kisqali Overview

Ribociclib (trade name Kisqali[1]) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer.[2] It is also being studied as a treatment for other drug-resistant cancers.[3] It was developed by Novartis and Astex Pharmaceuticals.[4] Contents 1 Medical uses 2 Side effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Research 6 Chemistry 7 See ...

Read more Kisqali Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ribociclib

Recent Kisqali Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ribociclib
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kisqali: (3 results)

Sorted by National Drug Code
  • 0078-0860 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0867 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-0874 Kisqali 200 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Ribociclib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 13 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA